trending Market Intelligence /marketintelligence/en/news-insights/trending/Kjyuh1MWXVWvXScmFR_cSg2 content esgSubNav
In This List

Cancer genomics company Personalis files for IPO

Podcast

Street Talk | Episode 94: Recessionary fears in ’22 overblown, Fed could overtighten

Blog

Insight Weekly: Ukraine war impact on mining; US bank growth slowdown; cloud computing headwinds

Blog

Insight Weekly: Cryptocurrency's growth; green bond market outlook; coal investors' windfall

Blog

Global M&A By the Numbers: Q1 2022


Cancer genomics company Personalis files for IPO

Personalis Inc. filed for an IPO of an undisclosed number of common shares.

The proposed maximum offering price, estimated solely to calculate the registration fee, is $115.0 million.

The cancer genomics company said it plans to use the net proceeds to expand its research and development efforts, infrastructure, facilities, and head count, as well as to fund its sales and marketing costs, public company costs, capital expenditures, and working capital. Part of the net proceeds may also go toward acquisitions or strategic investments in complementary businesses, services, products or technologies.

The Menlo Park, Calif.-headquartered emerging growth company applied to list its common stock on The Nasdaq Global Market under the PSNL ticker, according to a filing. The company's shareholders include Lightspeed Venture Partners, Abingworth LLP's Abingworth Bioventures V LP fund and funds managed by Mohr Davidow Ventures.

Morgan Stanley & Co. LLC, BofA Securities Inc., Cowen and Co. LLC and Oppenheimer & Co. Inc. are the underwriters for the IPO.